Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
Drug budget and prescription control measures are implemented regionally in Germany, meaning that the uptake of pharmaceuticals, including biosimilars, can vary by region. We examine regional market dynamics of tumor necrosis factor alpha (TNFα) inhibitor originators and biosimilars in Germany and s...
Saved in:
Main Authors: | Evelien Moorkens (Author), Teresa Barcina Lacosta (Author), Arnold G. Vulto (Author), Martin Schulz (Author), Gabriele Gradl (Author), Salka Enners (Author), Gisbert Selke (Author), Isabelle Huys (Author), Steven Simoens (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2020-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
by: Teresa Barcina Lacosta, et al.
Published: (2022) -
Economic evaluation of biosimilars for reimbursement purposes - what, when, how?
by: Evelien Moorkens, et al.
Published: (2020) -
An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
by: Evelien Moorkens, et al.
Published: (2020) -
Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
by: Tim A. Kanters, et al.
Published: (2017) -
Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
by: Liese Barbier, et al.
Published: (2022)